3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Status
Recruiting
3
Completed
3
Unknown
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
18
Tumor-Agnostic
3
Thoracic
3
Head & Neck
3
CNS
2
Other solid neoplasm
1
Myeloid
1
Gynecologic
1
Conditions
Neoplasms
3
Neoplasm Metastasis
2
Interventions
pembrolizumab
26
Specimen Handling
17
Blood Specimen Collection
17
Biopsy
16
Magnetic Resonance Spectroscopy
15
atezolizumab
11
Surveys and Questionnaires
11
Bevacizumab
9
Radiotherapy
8
Radiosurgery
8
Nivolumab
8
Fluorouracil
8
Standard of Care
7
Paclitaxel
7
Irinotecan
7
Gemcitabine
7
Cisplatin
7
olaparib
6
durvalumab
6
Palliative Care
6
Oxaliplatin
6
Leucovorin
6
Cyclophosphamide
6
Carboplatin
6
Capecitabine
6
alectinib
5
abemaciclib
5
Trastuzumab
5
Interviews as Topic
5
Exercise
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Panitumumab
×
Tumor-Agnostic
×
Clear all
NCT07021898
2025-12-03
BOREALIS-1
Erasca, Inc.
Phase 1
Recruiting
200 enrolled
NCT06983743
2025-09-11
AURORAS-1
Erasca, Inc.
Phase 1
Recruiting
200 enrolled
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled